NeoGenomics NEO announces its next round of earnings Tuesday. Here is Benzinga's everything-that-matters guide for the Q2 earnings announcement.
Earnings and Revenue
Wall Street analysts see NeoGenomics reporting earnings of 4 cents per share on sales of $66.1 million.
In the same quarter last year, NeoGenomics posted a loss of 4 cents on sales of $66 million. NeoGenomics's reported EPS has stacked up against analyst estimates in the past like this:
| Quarter | Q1 2018 | Q4 2017 | Q3 2017 | Q2 2017 |
| EPS Estimate | 0.03 | 0.04 | 0.04 | 0.03 |
| EPS Actual | 0.04 | 0.05 | 0.01 | 0.04 |
Stock Performance
Over the last 52-week period, shares are up 53.65 percent. Given that these returns are generally positive, long-term shareholders are probably satisfied going into this earnings release. Over the past 90 days, analysts have generally not modified their estimates for EPS and revenues. The average rating by analysts on NeoGenomics stock is a Neutral. The strength of this rating has maintained conviction over the past 90 days.
Conference Call
NeoGenomics' Q2 conference call is scheduled to begin at 8:30 a.m. ET and can be accessed here: http://www.investorcalendar.com/event/33517
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
